“The markets are dead!”: Emerita Resources (EMO.V) shows otherwise with massive upside coming
Lithium Ionic (LTH.V) is up 50% in 3 months, and is moving toward production
Digital Twinning, and how EdgeTI (CTRL.V) is a serious story you’ve never heard of
Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
Why Prospera Energy (PEI.V) might be a transformational investment opportunity in Canadian oil & gas
Sparc AI (SPAI.C) completes development of drone advanced target acquisition system
Lexaria Bioscience (LLX.C) announced today that treatment and dosing in its human clinical study, HYPER-H21-1, have been completed ahead of schedule. Read full article here: https://equity.guru/2021/06/07/lexaria-bioscience-lxx-c-releases-progress-report-for-first-human-clinical-study/
